Canadians Need Improved Access to Drugs for Rare Diseases, Not More Denial.

Q3 Medicine

Healthcare Papers Pub Date : 2023-04-01 DOI:10.12927/hcpap.2023.27112

Nigel S B Rawson, John Adams

引用次数: 0

Abstract

Sirrs et al. (2023a) discuss what they consider "explosive growth" (p. 11) in the research and development (R&D) and commercialization of expensive drugs for rare diseases (DRDs). They contend that the "status quo is no longer an option" (Sirrs et al. 2023b: 75), so it is critical to drastically reduce the prices of DRDs and/or ration access.

查看原文本刊更多论文

加拿大人需要改善罕见病药物的获取，而不是更多的拒绝。

Sirrs等人（2023a）讨论了他们认为的罕见病昂贵药物的研发和商业化中的“爆炸性增长”（第11页）。他们认为，“现状不再是一种选择”（Sirrs等人，2023b:75），因此大幅降低DRD和/或定量供应的价格至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Healthcare Papers Medicine-Health Policy

CiteScore

2.50

自引率

0.00%

发文量

期刊介绍： Integrating community-based health and social care has grabbed international attention as a way of addressing the needs of aging populations while contributing to health systems" sustainability. However, integrating initiatives in different jurisdictions work (or do not work) within very various.